No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study.
Ishii J, Nishikimi M, De Bus L, De Waele J, Takaba A, Kuriyama A, Kobayashi A, Tanaka C, Hashi H, Hashimoto H, Nashiki H, Shibata M, Kanamoto M, Inoue M, Hashimoto S, Katayama S, Fujiwara S, Kameda S, Shindo S, Komuro T, Kawagishi T, Kawano Y, Fujita Y, Kida Y, Hara Y, Yoshida H, Fujitani S, Shime N; DIANA study Japanese group.
Ishii J, et al. Among authors: yoshida h.
Microbiol Spectr. 2024 Jun 12:e0034224. doi: 10.1128/spectrum.00342-24. Online ahead of print.
Microbiol Spectr. 2024.
PMID: 38864641
Free article.